Catabasis Pharmaceuticals Inc

Please note: The information displayed on this page might be outdated.
Catabasis Pharmaceuticals Inc: Rare disease pipeline; Top-line results expected 2020 from ongoing Ph 3 trial of Edasalonexent in in DMD regardless of mutation type. North Star Ambulatory Assessment as primary endpt based on Ph 2 results and FDA input.
Based in...
US - New England
Clinical Stage
Phase III
Disease Space
Rare Disease
Public, USA
Market Cap
Therapeutic Modalities
Platform Technology, Small Molecule
One Kendall Square
Bldg. 1400E, Suite B14202
Cambridge, MA 02139
United States

Company Participants at Catabasis Pharmaceuticals Virtual KOL Event - Sep. 11, 2020

  • Jill C Milne, PhD, President/CEO/Co-Founder

Top 10 Holders of Catabasis Pharmaceuticals Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Federated Global Investment Management Corp. 10.90 1,950,000 4.37 Stakes 3/31/21
Perceptive Advisors LLC 10.80 1,933,551 4.33 Stakes 1/28/21
The Vanguard Group, Inc. 4.74 849,052 1.90 Funds 2/28/21
Vanguard Group, Inc. (Subfiler) 4.41 788,431 1.77 13F 12/31/20
BlackRock Fund Advisors 3.71 664,472 1.49 13F 12/31/20
Ikarian Capital LLC 3.63 650,000 1.46 13F 12/31/20
Morgan Stanley Capital Services LLC 3.41 609,498 1.37 13F 12/31/20
Eversept Partners LP 2.92 522,042 1.17 13F 12/31/20
BlackRock Institutional Trust Co. NA 2.12 379,887 0.85 13F 12/31/20
State Street Corp. 2.04 365,826 0.82 13F 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.